362 related articles for article (PubMed ID: 10759015)
41. Implementation of a 20-nm pore-size filter in the plasma-derived factor VIII manufacturing process.
Furuya K; Murai K; Yokoyama T; Maeno H; Takeda Y; Murozuka T; Wakisaka A; Tanifuji M; Tomono T
Vox Sang; 2006 Aug; 91(2):119-25. PubMed ID: 16907872
[TBL] [Abstract][Full Text] [Related]
42. Removal of small non-enveloped viruses by nanofiltration.
Yokoyama T; Murai K; Murozuka T; Wakisaka A; Tanifuji M; Fujii N; Tomono T
Vox Sang; 2004 May; 86(4):225-9. PubMed ID: 15144526
[TBL] [Abstract][Full Text] [Related]
43. Effect of viral nucleic acid testing on contamination frequency of manufacturing plasma pools.
Nübling CM; Unkelbach U; Chudy M; Seitz R
Transfusion; 2008 May; 48(5):822-6. PubMed ID: 18208414
[TBL] [Abstract][Full Text] [Related]
44. A solvent/detergent-treated and 15-nm filtered factor VIII: a new safety standard for plasma-derived coagulation factor concentrates.
Chtourou S; Porte P; Nogré M; Bihoreau N; Cheesman E; Samor B; Sauger A; Raut S; Mazurier C
Vox Sang; 2007 May; 92(4):327-37. PubMed ID: 17456157
[TBL] [Abstract][Full Text] [Related]
45. Removal of small nonenveloped viruses by antibody-enhanced nanofiltration during the manufacture of plasma derivatives.
Kreil TR; Wieser A; Berting A; Spruth M; Medek C; Pölsler G; Gaida T; Hämmerle T; Teschner W; Schwarz HP; Barrett PN
Transfusion; 2006 Jul; 46(7):1143-51. PubMed ID: 16836561
[TBL] [Abstract][Full Text] [Related]
46. Failure to detect hepatitis A virus RNA in factor VIII concentrates using the polymerase chain reaction. Results of a preliminary study.
McOmish F; Yap PL; Hart H; Peerlinck K; Burns SM; Simmonds P
Vox Sang; 1994; 67 Suppl 1():47-50. PubMed ID: 8091737
[TBL] [Abstract][Full Text] [Related]
47. Parvovirus B19 transmission by a high-purity factor VIII concentrate.
Wu CG; Mason B; Jong J; Erdman D; McKernan L; Oakley M; Soucie M; Evatt B; Yu MY
Transfusion; 2005 Jun; 45(6):1003-10. PubMed ID: 15935000
[TBL] [Abstract][Full Text] [Related]
48. Inactivation of HTLV-III/LAV, hepatitis B and non-A/non-B viruses by pasteurization in human plasma protein preparations.
Mauler R; Merkle W; Hilfenhaus J
Dev Biol Stand; 1987; 67():337-51. PubMed ID: 3111911
[TBL] [Abstract][Full Text] [Related]
49. The safety of fibrin sealants.
Joch C
Cardiovasc Surg; 2003 Aug; 11 Suppl 1():23-8. PubMed ID: 12869985
[TBL] [Abstract][Full Text] [Related]
50. Inactivation of parvovirus B19 during STIM-4 vapor heat treatment of three coagulation factor concentrates.
Berting A; Modrof J; Unger U; Gessner M; Klotz A; Poelsler G; Kreil TR
Transfusion; 2008 Jun; 48(6):1220-6. PubMed ID: 18410254
[TBL] [Abstract][Full Text] [Related]
51. Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety.
Herring SW; Abildgaard C; Shitanishi KT; Harrison J; Gendler S; Heldebrant CM
J Lab Clin Med; 1993 Mar; 121(3):394-405. PubMed ID: 8445288
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of an automated high-volume extraction method for viral nucleic acids in comparison to a manual procedure with preceding enrichment.
Hourfar MK; Schmidt M; Seifried E; Roth WK
Vox Sang; 2005 Aug; 89(2):71-6. PubMed ID: 16101686
[TBL] [Abstract][Full Text] [Related]
53. Inactivation of AIDS-causing retroviruses by the manufacturing procedures for human plasma proteins.
Hilfenhaus J; Gregersen JP
Behring Inst Mitt; 1988 Apr; (82):82-93. PubMed ID: 3044347
[TBL] [Abstract][Full Text] [Related]
54. Viral safety of recombinant factor IX.
Adamson S; Charlebois T; O'Connell B; Foster W
Semin Hematol; 1998 Apr; 35(2 Suppl 2):22-7. PubMed ID: 9565163
[TBL] [Abstract][Full Text] [Related]
55. Prevalence of Parvovirus B19 and Hepatitis A virus in Portuguese blood donors.
Henriques I; Monteiro F; Meireles E; Cruz A; Tavares G; Ferreira M; Araújo F
Transfus Apher Sci; 2005 Nov; 33(3):305-9. PubMed ID: 16203176
[TBL] [Abstract][Full Text] [Related]
56. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization.
Santagostino E; Mannucci PM; Gringeri A; Azzi A; Morfini M; Musso R; Santoro R; Schiavoni M
Transfusion; 1997 May; 37(5):517-22. PubMed ID: 9149778
[TBL] [Abstract][Full Text] [Related]
57. Pathogen safety of human C1 esterase inhibitor concentrate.
Gröner A; Nowak T; Schäfer W
Transfusion; 2012 Oct; 52(10):2104-12. PubMed ID: 22413956
[TBL] [Abstract][Full Text] [Related]
58. Removal of viral contaminants by monoclonal antibody purification of plasma proteins.
Schreiber AB; Hrinda ME; Newman J; Tarr GC; D'Alisa R; Curry WM
Curr Stud Hematol Blood Transfus; 1989; (56):146-53. PubMed ID: 2491983
[TBL] [Abstract][Full Text] [Related]
59. [Plasma fractionation. Progress, problems and perspectives].
Burnouf T
Ann Pharm Fr; 1994; 52(3):124-36. PubMed ID: 7998759
[TBL] [Abstract][Full Text] [Related]
60. Prevention of iatrogenic transmission of B19 infection: different approaches to detect, remove or inactivate virus contamination.
Bonvicini F; Gallinella G; Gentilomi GA; Ambretti S; Musiani M; Zerbini M
Clin Lab; 2006; 52(5-6):263-8. PubMed ID: 16812953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
